Every Condition We Treat —
and the Evidence Behind It.

Single-session interruption of acute opioid withdrawal and craving — the most-studied indication for ibogaine.

Modified protocol for the highest-potency synthetic opioid epidemic — extended washout, careful dosing.

Receptor-level interruption of heroin withdrawal, with fentanyl-contamination screening built into the protocol.

Resets alcohol craving and behavioral patterns; medically managed withdrawal first, since alcohol detox can be dangerous.

Disrupts dopaminergic-mediated craving cycles for cocaine, methamphetamine, and prescription stimulants.

Single-session resolution of kratom withdrawal and opioid receptor dependency.

Specialized tapering and washout protocol for long-acting opioid replacement therapies.

Coordinated benzo taper combined with ibogaine for combined opioid-benzo dependence.

Resets nicotinic receptor sensitization; multi-day craving extinction window.

Rapid-onset antidepressant effect with neuroplasticity promotion; particularly for SSRI-failed depression.

Generalized and panic anxiety reduction with sustained effect after a single session.

Disrupts compulsive thought-loop patterns; emerging evidence for treatment-resistant OCD.

Targets underlying trauma and reward-circuit dysregulation in anorexia, bulimia, BED.

Rapid reduction in suicidal ideation paired with extended psychiatric follow-up.

10-14 day supervised protocol resetting the serotonin system for safe antidepressant discontinuation.

Trauma-focused ibogaine therapy with structured integration; the most-cited use among veterans.

Complex post-traumatic stress from prolonged or developmental trauma; extended integration window.

Specialized program for combat-related PTSD frequently with comorbid TBI and substance use.

Combat and blast-related TBI — neuroplasticity and neurotrophic support, informed by the 2024 Stanford veterans study.

Police, fire, EMS, and dispatch-specific trauma protocols.

GDNF upregulation and dopaminergic neuron repair — the most-discussed neurodegenerative indication.

Anti-neuroinflammatory and neuroplastic mechanisms applied to MS symptom management.

A mechanism-based, anti-inflammatory approach for early decline — offered with full candor and never as a cure.

Neurotrophic and anti-inflammatory support, safety-gated and honest about the limits of the evidence.

Neurotrophic (BDNF) and anti-inflammatory support with a focus on HD's psychiatric burden, safety-gated and honest about the evidence.

Central sensitization disruption, opioid receptor reset, and inflammatory modulation.